Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

APPY 0.410 -0.016 (-3.67%)
price chart
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Drops by -0.22%
Venaxis, Inc. (NASDAQ:APPY) has lost 0.22% during the past week and dropped 8.66% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 1.12%.
Form 8-K Venaxis, Inc. For: Apr 07
These forward-looking statements are qualified by the cautionary statements contained in Venaxis' news releases and SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2014, which Venaxis filed on March 30, 2015.
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
Venaxis, Inc. Price Target Update
Venaxis, Inc. shares have received a Mean Price Target of $0.75. According to the rating issued from 2 Wall Street Analysts, the High Price Target is seen at $1 while the Lower end of the Price Target is seen at $0.5.
Shares of Venaxis, Inc. (NASDAQ:APPY) Drops by -1.22%
Venaxis, Inc. (NASDAQ:APPY) has lost 1.22% during the past week and dropped 7.98% in the last 4 weeks. The shares have outperformed the S&P 500 by 4.83% in the past week but underperformed the index by 2.9% in the last 4 weeks.
Short Interest Update on Venaxis, Inc. (NASDAQ:APPY)
The short interest in Venaxis, Inc. (NASDAQ:APPY) has declined from 1,329,500 on July 15,2015 to 1,270,672 on July 31,2015.
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Venaxis' appendicitis test not found equivalent to standard care  Reuters
Venaxis Business Update
CASTLE ROCK, Colo., June 22, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, ...
Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)
With news being very light on names that I cover over the past few weeks, I wanted to initiate a new name today: Venaxis (NASDAQ:APPY).